We treated PCa cells with THZ531 and first- (bicalutamide) or next-generation AR antagonists (apalutamide and enzalutamide), and found synergy with no limitation to a single antagonist or cell line (Fig. 5A). The gene discussed is AR; the disease is posterior cortical atrophy.